Back to Stocks

ORGO

Organogenesis Holdings Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Organogenesis Holdings is positioning itself as a lean, cash-efficient entity following a period of significant regulatory turbulence. The first quarter of 2026 marked a critical financial inflection point, as the company swung to a positive operating cash flow of $21.1 million.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The narrative of a financial recovery is challenged by a staggering 58% collapse in net product revenue, which fell to $36.3 million in the first quarter of 2026.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ORGO filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a stark contrast between a deteriorating top line and a disciplined approach to liquidity management. Organogenesis is effectively trading short-term growth for survival, using aggressive working capital optimization to fund a strategic pivot toward new product launches and operational efficiency. The massive collection of receivables provides a necessary cushion, but it does not solve the underlying problem of a shrinking market for its primary wound care offerings. Investors are now faced with a binary outcome centered on regulatory clarity and product approval. If the ReNu BLA is successful and CMS reimbursement stabilizes, the company's lean cost structure and strong cash position could lead to a rapid re-rating. However, if the revenue decline persists and the Smithfield facility faces further delays, the current cash reserves may only serve to delay an inevitable liquidity crisis. The immediate focus remains on the August 2026 credit expiration and the progress of the ReNu submission.

Selected Quarter

Core Takeaway

The company is successfully optimizing its balance sheet to survive a severe regulatory-driven revenue slump while betting on a new product pipeline.

Investor Lens

The trade-off is between the current valuation floor (cash/assets) and the high risk of continued top-line decay.

Watch Next

The expiration of the Revolving Facility on August 6, 2026, and FDA feedback on the ReNu BLA.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.25Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Net product revenue collapsed 58% year-over-year due to regulatory disruptions.

earnings miss
90%
bearishMay 7

Gross profit plummeted from $63M to $10.5M due to volume loss and inventory write-downs.

margin compression
70%
neutralMay 7

Implemented restructuring plan reducing headcount by 10% and closing Florida facility.

management change
40%
bullishMay 7

Strong liquidity position with $91.4M cash and $75M available revolving credit.

capital raise
60%
bearishMay 7

Net product revenue collapsed 58% year-over-year due to regulatory disruptions.

earnings miss
90%
bearishMay 7

Gross profit plummeted from $63M to $10.5M due to volume loss and inventory write-downs.

margin compression
70%
neutralMay 7

Implemented restructuring plan reducing headcount by 10% and closing Florida facility.

management change
40%
bullishMay 7

Strong liquidity position with $91.4M cash and $75M available revolving credit.

capital raise
60%
bearishMay 7

Net product revenue collapsed 58% year-over-year due to regulatory disruptions.

earnings miss
90%
bearishMay 7

Gross profit plummeted from $63M to $10.5M due to volume loss and inventory write-downs.

margin compression
70%
neutralMay 7

Implemented restructuring plan reducing headcount by 10% and closing Florida facility.

management change
40%
bullishMay 7

Strong liquidity position with $91.4M cash and $75M available revolving credit.

capital raise
60%
bearishMay 7

Net product revenue collapsed 58% year-over-year due to regulatory disruptions.

earnings miss
90%
bearishMay 7

Gross profit plummeted from $63M to $10.5M due to volume loss and inventory write-downs.

margin compression
70%
neutralMay 7

Implemented restructuring plan reducing headcount by 10% and closing Florida facility.

management change
40%
bullishMay 7

Strong liquidity position with $91.4M cash and $75M available revolving credit.

capital raise
60%
bearishMay 7

Net product revenue collapsed 58% year-over-year due to regulatory disruptions.

earnings miss
90%
bearishMay 7

Gross profit plummeted from $63M to $10.5M due to volume loss and inventory write-downs.

margin compression
70%
neutralMay 7

Implemented restructuring plan reducing headcount by 10% and closing Florida facility.

management change
40%
bullishMay 7

Strong liquidity position with $91.4M cash and $75M available revolving credit.

capital raise
60%
bearishMay 7

Net product revenue collapsed 58% year-over-year due to regulatory disruptions.

earnings miss
90%
bearishMay 7

Gross profit plummeted from $63M to $10.5M due to volume loss and inventory write-downs.

margin compression
70%
neutralMay 7

Implemented restructuring plan reducing headcount by 10% and closing Florida facility.

management change
40%
bullishMay 7

Strong liquidity position with $91.4M cash and $75M available revolving credit.

capital raise
60%
bearishMay 7

Net product revenue collapsed 58% year-over-year due to regulatory disruptions.

earnings miss
90%
bearishMay 7

Gross profit plummeted from $63M to $10.5M due to volume loss and inventory write-downs.

margin compression
70%
neutralMay 7

Implemented restructuring plan reducing headcount by 10% and closing Florida facility.

management change
40%
bullishMay 7

Strong liquidity position with $91.4M cash and $75M available revolving credit.

capital raise
60%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a stark contrast between a deteriorating top line and a disciplined approach to liquidity management. Organogenesis is effectively trading short-term growth for survival, using aggressive working capital optimization to fund a strategic pivot toward new product launches and operational efficiency. The massive collection of receivables provides a necessary cushion, but it does not solve the underlying problem of a shrinking market for its primary wound care offerings. Investors are now faced with a binary outcome centered on regulatory clarity and product approval. If the ReNu BLA is successful and CMS reimbursement stabilizes, the company's lean cost structure and strong cash position could lead to a rapid re-rating. However, if the revenue decline persists and the Smithfield facility faces further delays, the current cash reserves may only serve to delay an inevitable liquidity crisis. The immediate focus remains on the August 2026 credit expiration and the progress of the ReNu submission.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.